These results indicated that the anti-NAFLD activity of Man is mediated by its anti-inflammatory effects via NLRP3 inflammasome inhibition (Yong, Ruiqi et al., 2021). The gene discussed is NLRP3; the disease is metabolic dysfunction-associated steatotic liver disease.